NordiMED
Evidence-based Decision Support Partner

Today, most healthcare companies experience that their brands are under increased pressure due to stricter demands for ROI on marketing and sales spending, heightened complexities to achieving market access, and shorter life cycles. As a result, it has become crucial to explore and track key performance indicators to navigate in the different therapeutic markets.

This is where NordiMED plays a vital role. Founded by a group of consultants and market researchers dedicated to understanding what drives commercial success in each therapy area, the company has emerged as an evidence-based decision support partner to the world’s leading healthcare companies.

“We deliver “to the point” results that help clients improve performance,” says Morten Søndberg, the CEO and Partner at NordiMED. “At NordiMED, our only focus is market research within healthcare and life sciences industry. We are working within all therapy areas and have a high level of experience and knowledge with a broad spectrum of disease areas.” This allows the company to minimize the time spend on informing, introducing and explaining about the issues within a therapy area.

We deliver “to the point” results that help clients improve performance

Mr Søndberg informs, “We can minimize the time clients spend on informing, introducing, and explaining about the issues within their therapy area that will support their specific decision making in driving performance.”

NordiMED takes an ethical responsibility in all its work. That’s why they work within the code of conduct of the market research standards such as ESOMAR, the pharmaceutical research association— EphMRA, and the local regulations in each country like ENLI, LiF, BHBIA, etc. By monitoring the safety, performance, and quality of clients’ products, the company forwards safety monitoring reports. Further, all personnel involved in market research at the company are trained to handle Adverse Events annually. The company encourages clients to forward their specific description of procedures related to Adverse Event handling. As a result, they can educate all the team members and rightly define the standard operating procedure for each client.

Although NordiMED is headquartered in the Nordic countries, the company works, coordinates and implements studies all across Europe. In all countries—same way, same design and yet with local language and local adjustments. Due to being small and flexible but big in Pharma, the company has doubled in size within the last three years. Currently, 85 percent of the world’s top 20 pharma companies are clients of NordiMED—in one or several European countries.

Truly, working in liaison with different types of healthcare market research and conducting quantitative, qualitative and both syndicated and customized studies, the company has always focused on making clients’ sales and marketing strategies more effective.